These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 28506255)

  • 1. Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery.
    Uemura M; Qiao W; Fournier K; Morris J; Mansfield P; Eng C; Royal RE; Wolff RA; Raghav K; Mann GN; Overman MJ
    BMC Cancer; 2017 May; 17(1):331. PubMed ID: 28506255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of cytoreductive surgery on outcomes of metastatic appendiceal carcinoma: a real-world, population-based study.
    Abdel-Rahman O
    J Comp Eff Res; 2020 Apr; 9(6):431-439. PubMed ID: 32253936
    [No Abstract]   [Full Text] [Related]  

  • 3. The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base.
    Asare EA; Compton CC; Hanna NN; Kosinski LA; Washington MK; Kakar S; Weiser MR; Overman MJ
    Cancer; 2016 Jan; 122(2):213-21. PubMed ID: 26506400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms.
    Choe JH; Overman MJ; Fournier KF; Royal RE; Ohinata A; Rafeeq S; Beaty K; Phillips JK; Wolff RA; Mansfield PF; Eng C
    Ann Surg Oncol; 2015 Aug; 22(8):2578-84. PubMed ID: 25582740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA).
    Milovanov V; Sardi A; Ledakis P; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
    Eur J Surg Oncol; 2015 May; 41(5):707-12. PubMed ID: 25633641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of adjuvant chemotherapy on outcomes in appendiceal cancer.
    Kolla BC; Petersen A; Chengappa M; Gummadi T; Ganesan C; Gaertner WB; Blaes A
    Cancer Med; 2020 May; 9(10):3400-3406. PubMed ID: 32189461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extensive surgical history prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with poor survival outcomes in patients with peritoneal mucinous carcinomatosis of appendiceal origin.
    Milovanov V; Sardi A; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
    Eur J Surg Oncol; 2015 Jul; 41(7):881-5. PubMed ID: 25899982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early postoperative intraperitoneal chemotherapy following cytoreductive surgery for appendiceal mucinous neoplasms with isolated peritoneal metastasis.
    Wagner PL; Jones D; Aronova A; Shia J; Weiser MR; Temple LK; Chung KY; O'Reilly EM; Kelsen D; Paty PB; Nash GM
    Dis Colon Rectum; 2012 Apr; 55(4):407-15. PubMed ID: 22426264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic chemotherapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade mucinous carcinoma peritonei of appendiceal origin.
    Munoz-Zuluaga CA; King MC; Ledakis P; Gushchin V; Sittig M; Nieroda C; Zambrano-Vera K; Sardi A
    Eur J Surg Oncol; 2019 Sep; 45(9):1598-1606. PubMed ID: 31109821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis.
    El Halabi H; Gushchin V; Francis J; Athas N; Macdonald R; Nieroda C; Studeman K; Sardi A
    Ann Surg Oncol; 2012 Jan; 19(1):110-4. PubMed ID: 21701929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 7th Edition of the AJCC Staging Classification Correlates with Biologic Behavior of Mucinous Appendiceal Tumor with Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Milovanov V; Sardi A; Studeman K; Nieroda C; Sittig M; Gushchin V
    Ann Surg Oncol; 2016 Jun; 23(6):1928-33. PubMed ID: 26714951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis.
    Glockzin G; Gerken M; Lang SA; Klinkhammer-Schalke M; Piso P; Schlitt HJ
    BMC Cancer; 2014 Nov; 14():807. PubMed ID: 25369730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse Events Postoperatively Had No Impact on Long-Term Survival of Patients Treated with Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Appendiceal Cancer with Peritoneal Metastases.
    Ihemelandu C; Mavros MN; Sugarbaker P
    Ann Surg Oncol; 2016 Dec; 23(13):4231-4237. PubMed ID: 27338748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
    Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
    Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological Subtype Remains a Significant Prognostic Factor for Survival Outcomes in Patients With Appendiceal Mucinous Neoplasm With Peritoneal Dissemination.
    Huang Y; Alzahrani NA; Chua TC; Morris DL
    Dis Colon Rectum; 2017 Apr; 60(4):360-367. PubMed ID: 28267002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Adjuvant Chemotherapy Following Right Hemicolectomy for Non-metastatic Mucinous and Nonmucinous Appendiceal Adenocarcinoma.
    AlMasri SS; Paniccia A; Hammad AY; Pai RK; Bahary N; Zureikat AH; Medich DS; Celebrezze JP; Choudry HA; Nassour I
    J Gastrointest Surg; 2022 Jan; 26(1):171-180. PubMed ID: 34291365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection.
    Grotz TE; Overman MJ; Eng C; Raghav KP; Royal RE; Mansfield PF; Mann GN; Robinson KA; Beaty KA; Rafeeq S; Matamoros A; Taggart MW; Fournier KF
    Ann Surg Oncol; 2017 Sep; 24(9):2646-2654. PubMed ID: 28695394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin.
    Sugarbaker PH; Bijelic L; Chang D; Yoo D
    J Surg Oncol; 2010 Nov; 102(6):576-81. PubMed ID: 20737420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
    Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
    Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.